Home
Immutep Limited
ASX Code
IMM
Sector
Pharmaceuticals- Biotechnology & Life Sciences
Investor Centre
https://www.immutep.com/investors-media/whats-new.html
Website
https://www.immutep.com/
About
Global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or "LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases. IMM's objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.
News
Research
| Efti a highly sought after compound for mono & combo Cancer treatment | |
| A Truly Undervalued Company |